Tag:
Henri Termeer
Latest Headlines
Latest Headlines
Ex-Genzyme CEO to serve as Prosensa's strategic adviser
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant ( email | Twitter ) and we will feature it...
Outgoing Genzyme CEO Termeer hops on to AVEO board
Henri Termeer ( photo ) is leaving the newly acquired Genzyme with a severance deal worth potentially more than $200 million, but he'll be keeping his finger in the biotech game as a new director of
Genzyme's Termeer to pocket up to $221M
Genzyme CEO Henri Termeer, 2010's top biopharma whipping boy, will leave the biotech with at least $158.4 million, according to Bloomberg. Citing regulatory filings, the news service adds that
Sanofi, Genzyme chiefs cite progress in merger talks
Yesterday Sanofi ( $SNY ) CEO Chris Viehbacher ( photo ) got a chance to sound mildly positive about the chances of hashing out a merger pact with Genzyme ( $GENZ ). And today Genzyme CEO Henri Termeer (
Termeer counsels patience on Sanofi bid
Speaking to a Chamber group in Boston yesterday Genzyme's Henri Termeer ( photo ) made it clear that he's going to sit tight until he can hammer out an acceptable offer for the company. "It took us 30
Termeer: "It can't go on forever"
Genzyme's CEO spent a good part of Monday burnishing the prospects of their experimental MS drug alemtuzumab, and thereby the value of the big biotech. With Sanofi so far unwilling to budge from its
Sources: Genzyme ($GENZ) floats $82 bid by Takeda
Anxious to stir up a bidding war, Genzyme ( $GENZ ) has reportedly initiated a discussion with Japan's Takeda around an $82-per-share target offer, according to a number of press reports. Takeda is
Dear Henri: Sanofi chief advises Genzyme against defensive moves
Sanofi-Aventis ( $SNY ) CEO Chris Viehbacher ( photo ) sounds a little miffed that Genzyme's ( $GENZ ) board would be out encouraging new bids for the big biotech without even so much as a lunch date to
Genzyme's Termeer loses millions at $69 per share
Genzyme CEO Henri Termeer ( photo ) may have a selfish reason for refusing Sanofi-Aventis' $69-per-share offer. Yes, Termeer would get a big buyout bonus--$11 million by some estimates--but that bonus
Sanofi-Genzyme takeover bid gets heated
It's been a busy morning with Sanofi-Aventis-Genzyme news. According to news reports, Sanofi is denying suggestions by Genzyme that it privately offered a higher price for the Cambridge, MA-based
